Why Cardiologists Are Looking Beyond Traditional SGLT2 Therapy

The treatment landscape for type 2 diabetes has changed dramatically over the past decade. While selective SGLT2 inhibitors have become a cornerstone of diabetes management because of their proven cardiovascular and kidney benefits, researchers are now exploring the added potential of dual SGLT1/2 inhibitor therapy for people with diabetes. By targeting both glucose absorption in the intestine and glucose reabsorption in the kidneys, dual inhibitors offer a unique approach that extends beyond blood sugar control.

Among these medications, sotagliflozin (Inpefa®) has attracted considerable attention following major clinical trials demonstrating meaningful reductions in heart failure events in patients with and without diabetes. Consequently, cardiologists are increasingly viewing these therapies as valuable tools in the growing field of cardiometabolic medicine.

Table of Contents

• Understanding SGLT1 and SGLT2
• How Dual SGLT1/2 Inhibitors Improve Blood Sugar Control in Diabetes
• Heart Failure Benefits Beyond Glucose Control
• Where Dual Inhibitors May Fit in Future Diabetes Care
• Conclusion
• Frequently Asked Questions

Understanding the Difference Between SGLT1 and SGLT2

To understand why dual SGLT1/2 inhibitor therapy is generating excitement in diabetes care, it helps to understand how these transport proteins function.

SGLT2 proteins are located primarily in the kidneys. They are responsible for reabsorbing approximately 90% of filtered glucose back into the bloodstream. Selective SGLT2 inhibitors block this process, allowing excess glucose to be excreted in the urine. As a result, patients experience lower blood glucose levels, modest weight loss, lower blood pressure, and significant reductions in heart failure hospitalization.

SGLT1 proteins, however, serve a different purpose. They are found mainly in the small intestine, where they regulate dietary glucose absorption after meals. In addition, they are present in the heart and kidneys, although their exact cardiovascular role continues to be investigated.

Because dual inhibitors block both transporters, they reduce post-meal glucose absorption while maintaining the renal glucose-lowering effects seen with selective SGLT2 inhibitors. Therefore, they offer a broader metabolic strategy than kidney-targeted therapy alone.

For a comprehensive overview of SGLT inhibition, the American Diabetes Association provides regularly updated clinical guidance.

How Dual SGLT1/2 Inhibitors Improve Blood Sugar Control in Diabetes

The primary advantage of dual SGLT1/2 inhibitor therapy is its complementary mechanism of action.

Unlike selective SGLT2 inhibitors, sotagliflozin slows intestinal glucose absorption immediately after meals. Consequently, patients often experience lower postprandial glucose excursions, which contribute substantially to overall HbA1c levels.

At the same time, continued inhibition of SGLT2 promotes urinary glucose excretion throughout the day. Together, these mechanisms create more consistent glucose control without relying on increased insulin secretion.

Clinical studies have demonstrated that sotagliflozin lowers HbA1c while also contributing to modest weight reduction and lower systolic blood pressure. Furthermore, because the medication works independently of insulin, the risk of hypoglycemia remains relatively low unless combined with insulin or insulin secretagogues.

Researchers also continue to investigate whether delayed intestinal glucose absorption favorably influences incretin hormones such as GLP-1. Although this area requires further study, it may partially explain some of the additional metabolic benefits observed in clinical trials.

Healthcare professionals seeking detailed therapeutic updates can explore additional diabetes treatment resources throughout Diabetes In Control.

Why Cardiologists Are Paying Close Attention

Cardiologists initially embraced SGLT2 inhibitors because cardiovascular outcome trials consistently demonstrated reductions in heart failure hospitalization regardless of diabetes status.

Dual inhibitors appear to extend these benefits even further in selected populations.

The SOLOIST-WHF trial evaluated sotagliflozin in patients recently hospitalized for worsening heart failure. Investigators found significant reductions in cardiovascular deaths, hospitalizations, and urgent heart failure visits compared with placebo. Importantly, benefits appeared soon after treatment initiation.

Similarly, the SCORED trial demonstrated reductions in cardiovascular events among patients with chronic kidney disease and type 2 diabetes, despite early termination related to funding rather than safety concerns.

These findings have shifted cardiologists’ attention toward therapies that address both metabolic disease and cardiovascular outcomes simultaneously.

Heart failure specialists particularly value treatments that reduce recurrent hospitalizations because each admission substantially increases long-term mortality risk. Therefore, therapies capable of improving glycemic control while lowering heart failure events represent an attractive option within comprehensive cardiometabolic care.

The American Heart Association continues to recognize SGLT inhibition as an important component of modern heart failure management.

Where Dual SGLT1/2 Inhibitors May Fit in the Future

Although selective SGLT2 inhibitors remain foundational therapies, dual SGLT1/2 inhibitors for diabetes may occupy a growing role as clinical experience expands.

Patients with type 2 diabetes and established heart failure may derive particular benefit from therapies that address both glucose regulation and cardiovascular protection simultaneously. Likewise, individuals with chronic kidney disease represent another population where ongoing research continues to define optimal treatment strategies.

However, clinicians must also consider potential adverse effects. Similar to other medications within this class, genital fungal infections remain relatively common. Diabetic ketoacidosis, although uncommon, requires careful patient education, particularly among insulin-treated individuals.

In addition, transient gastrointestinal symptoms may occur because of intestinal SGLT1 inhibition. Fortunately, these effects are generally manageable with appropriate patient counseling.

As evidence continues to accumulate, professional guidelines will likely further clarify which patients benefit most from dual inhibition. Consequently, cardiologists, endocrinologists, nephrologists, and primary care physicians are increasingly collaborating within integrated cardiometabolic care models.

Patients considering newer diabetes medications should discuss treatment options with qualified healthcare providers. Additional educational resources are available through Healthcare.pro.

Conclusion

Dual SGLT1/2 inhibitor therapy represents an important evolution beyond traditional SGLT2 inhibition, offering a broader cardiometabolic approach for people living with diabetes. By simultaneously reducing intestinal glucose absorption and renal glucose reabsorption, medications such as sotagliflozin provide improved glycemic control while delivering meaningful cardiovascular benefits, particularly in patients at risk for heart failure.

As cardiometabolic medicine continues to evolve, therapies that address multiple disease pathways simultaneously are becoming increasingly valuable. Although additional long-term research will continue to refine their role, dual SGLT1/2 inhibitors have already established themselves as promising additions to modern diabetes and cardiovascular care.

Frequently Asked Questions

What is a dual SGLT1/2 inhibitor?

A dual SGLT1/2 inhibitor blocks glucose transport in both the small intestine and kidneys, improving blood sugar control through two complementary mechanisms.

Which medication is currently the best-known dual SGLT1/2 inhibitor?

Sotagliflozin (Inpefa®) is currently the leading dual SGLT1/2 inhibitor with evidence supporting cardiovascular and heart failure benefits.

How is dual SGLT1/2 inhibitor therapy different from traditional SGLT2 inhibitors?

Traditional SGLT2 inhibitors primarily reduce kidney glucose reabsorption, whereas dual inhibitors also slow intestinal glucose absorption after meals.

Do dual SGLT1/2 inhibitors reduce heart failure risk?

Major clinical trials have shown that sotagliflozin significantly reduces heart failure hospitalizations and urgent heart failure visits in appropriate patient populations.

Who may benefit most from dual SGLT1/2 inhibitor therapy?

Patients with type 2 diabetes who also have heart failure or chronic kidney disease may benefit most, although treatment decisions should always be individualized.

Disclaimer: This content is not medical advice. For any health issues, always consult a healthcare professional. In an emergency, call 911 or your local emergency services.